Product Name
Lipoprotein, low density from human plasma, ≥95% (SDS-PAGE), solution
biological source
human plasma
assay
≥95% (SDS-PAGE)
form
solution
functional group
ester
phospholipid
shipped in
wet ice
storage temp.
2-8°C
Quality Level
Gene Information
human ... APOB(338), APOC2(344), APOE(348)
Looking for similar products? Visit Product Comparison Guide
Related Categories
Application
Lipoprotein, low density from human plasma has been used:
- as an additive in cholesterol-free RPMI media
- as a component in buffer to perform an assay for measuring lipid peroxidation
- to stimulate hepatic macrophages
- as a plasma protein to determine pazopanib unbound fraction (fu%) by equilibrium dialysis
Biochem/physiol Actions
LDL and HDL transport both dietary and endogenous cholesterol in the plasma. LDL is the main transporter of cholesterol and cholesteryl esters and makes up more than half of the total lipoprotein in plasma. LDL is absorbed by the liver and other tissues via receptor mediated endocytosis. The cytoplasmic domain of the LDL receptor facilitates the formation of coated pits; receptor-rich regions of the membrane. The ligand binding domain of the receptor recognizes apo-B100 on LDL, resulting in the formation of a clathrin-coated vesicle. ATP-dependent proton pumps lower the pH inside the vesicle resulting dissociation of LDL from its receptor. After loss of the clathrin coat the vesicles fuse with lysozomes, resulting in peptide and cholesteryl ester enzymatic hydrolysis. The LDL receptor can be recycled to the cell membrane. Insulin, tri-iodothyronine and dexamethasome have shown to be involved with the regulation of LDL receptor mediated uptake.
Disclaimer
Freezing of lipoprotein solutions may cause structural or compositional changes.
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
General description
Low density lipoproteins are smaller than VLDL and IDL (26 nm) (MW approximately 3.5 million) and more dense (~1.04). The protein component of LDL is apolipoprotein B100. LDL contains 20-22% protein, 10-15% triglycerides, 20-28% phospholipids, 37-48% cholesteryl esters and 8-10% cholesterol.
Other Notes
View more information on lipoprotein function and lipid transport at www.sigma-aldrich.com/enzymeexplorer
Physical form
Solution in 150 mM NaCl and 0.01% EDTA, pH 7.4
Storage Class
10 - Combustible liquids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Leanne Satchell et al.
Biochemistry, 51(18), 3767-3775 (2012-04-13)
Low-density lipoprotein (LDL) has recently been shown to be oxidized by iron within the lysosomes of macrophages, and this is a novel potential mechanism for LDL oxidation in atherosclerosis. Our aim was to characterize the chemical and physical changes induced
Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site
Imbs DC, et al.
Investigational New Drugs, 34(1), 41-48 (2016)
L L Rudel et al.
The Biochemical journal, 139(1), 89-95 (1974-04-01)
1. A simple method for isolation of individual human plasma lipoprotein classes is presented. In this technique, lipoproteins are removed from plasma at d1.225 by ultracentrifugation, after which they are separated and purified by agarose-column chromatography. 2. Three major classes
S P Zhao et al.
Clinica chimica acta; international journal of clinical chemistry, 203(2-3), 109-117 (1991-12-16)
After 15 weeks of simvastatin therapy (20 mg/day), low density lipoprotein particle size in sera of 16 patients with type IIb hyperlipoproteinemia increased significantly from 233 +/- 5.0 A to 237 +/- 7.0 A (P less than 0.05), analyzed by
Ezetimibe suppresses development of liver tumors by inhibiting angiogenesis in mice fed a high-fat diet
Miura K, et al.
Cancer Science, 110(2), 771-771 (2019)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service